Home

Athena Countouriotis

CIK 1571469 · President & CEO · last filed 2026-06-18

Athena Countouriotis is a President & CEO who has filed 45 SEC Form 4 insider transactions across 8 companies since 2013. The most recent filing, for IOVA, was dated Jun 18, 2026. Across all open-market trades the lifetime net is −$7.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.4M across reported positions. 5 SEC filings were submitted jointly with BIOMARIN PHARMACEUTICAL INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.39M

Companies

8

Total Filings

45

Lifetime Open-Market Net

-$7.13M

Filer Profile

Reported Address
C/O AMBIT BIOSCIENCES CORPORATION
11080 ROSELLE STREET
SAN DIEGO, CA 92121
Related Filers
BIOMARIN PHARMACEUTICAL INC — 5 joint filings, latest 2026-06-04
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
IOVA Director — $8.60 — $0 9 2026-06-18
BMRN Director 21,040 $65.68 $1.38M $0 4 2026-06-04
PASG Director 945 $5.00 $4.7K $309.9K 9 2026-05-21
Turning Point Therapeutics, Inc. (TPTX) Delisted President & CEO 0 $76.01 $0 -$7.44M 8 2022-08-17
Cardiff Oncology, Inc. (TROV) Delisted Director — — — $0 2 2019-06-24
Adverum Biotechnologies, Inc. (ADVM) Delisted SVP, Chief Medical Officer 15,000 $4.36 $65.4K $0 2 2018-02-20
HALOZYME THERAPEUTICS, INC. (HTI) Delisted SVP and Chief Medical Officer 45,977 — — $0 8 2017-02-24
AMBIT BIOSCIENCES CORP (AMBI) Delisted Chief Medical Officer — $0.54 — $0 3 2014-11-12

Recent Filings

45 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-18 IOVA Grant (A) — $0 EDGAR
2026-06-04 BMRN Grant (A) +7,490 $0 EDGAR
2026-05-21 PASG Grant (A) — $0 EDGAR
2025-06-17 IOVA Grant (A) — $0 EDGAR
2025-05-30 PASG Grant (A) — $0 EDGAR
2025-05-22 BMRN Grant (A) +6,650 $0 EDGAR
2024-06-13 IOVA Grant (A) — $0 EDGAR
2024-05-23 BMRN Grant (A) +4,720 $0 EDGAR
2024-05-23 PASG Grant (A) — $0 EDGAR
2024-03-05 IOVA Grant (A) — $0 EDGAR
Showing 1–10 of 45
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.